person
Óscar R. F.
- Country
- Spain
- Department
- Urology
Research Overview
assignment
11
Clinical Trials ·
- Phase II Study of Sasanlimab and Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of PF-08052667 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
- Evaluation of Safety and Anti-Tumor Activity of Intravesical TARA-002 in High-Grade Non-Muscle Invasive Bladder Cancer
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
95
Sites with multiple studies
Has run more than one trial at 95 of 246 partner sites.
Specializations
Non-Muscle Invasive Bladder Cancer Research
Specialized in investigating novel therapeutic approaches for high-risk non-muscle invasive bladder cancer (NMIBC), with particular focus on patients unresponsive to conventional treatments.
- BCG-unresponsive disease management
- Intravesical therapy innovations
- Combination immunotherapy approaches
Advanced Therapeutic Development
Conducts research on innovative treatment combinations including TAR-200 drug delivery systems and immune checkpoint inhibitors for bladder cancer therapy.
- Novel drug delivery systems
- Immunotherapy combinations
- Treatment-resistant cases
Muscle-Invasive Bladder Cancer Studies
Investigates treatment options for muscle-invasive urothelial carcinoma, focusing on alternatives to traditional therapeutic approaches.
- Neoadjuvant therapy alternatives
- Bladder-preserving strategies
- Chemoradiotherapy comparisons
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.